KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Divestments (2019 - 2022)

Boston Scientific's Divestments history spans 9 years, with the latest figure at $5.0 million for Q1 2022.

  • For Q1 2022, Divestments fell 99.38% year-over-year to $5.0 million; the TTM value through Dec 2022 reached $5.0 million, down 99.39%, while the annual FY2022 figure was $5.0 million, 99.39% down from the prior year.
  • Divestments for Q1 2022 was $5.0 million at Boston Scientific, down from $25.0 million in the prior quarter.
  • Across five years, Divestments topped out at $801.0 million in Q1 2021 and bottomed at $5.0 million in Q1 2022.
  • The 4-year median for Divestments is $25.0 million (2021), against an average of $187.2 million.
  • The largest YoY upside for Divestments was 99.38% in 2022 against a maximum downside of 99.38% in 2022.
  • A 4-year view of Divestments shows it stood at $90.0 million in 2019, then plummeted by 83.33% to $15.0 million in 2020, then surged by 66.67% to $25.0 million in 2021, then crashed by 80.0% to $5.0 million in 2022.
  • Per Business Quant, the three most recent readings for BSX's Divestments are $5.0 million (Q1 2022), $25.0 million (Q4 2021), and $801.0 million (Q1 2021).